This is link not to patents but to applications for patents. Check out at least the most recent one.
appft.uspto.gov:8080/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=xoma&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01
If a large trial is started by Baxter for Sepsis we should learn more about the 10 year agreement. Baxter pays 100% of all cost and milestones vary by the size of the indication.
[0001] This is a continuation of co-pending U.S. patent application Ser. No. 08/466,826 filed Jun. 6, 1995, which is a continuation of U.S. patent application
Ser. No. 08/415,158 filed Mar. 31, 1995, which is a file-wrapper-continuation of U.S. patent application Ser. No. 08/093,202 filed Jul. 15, 1993, which is a
continuation-in-part of U.S. patent application Ser. No. 08/030,644 filed Mar. 12, 1993.
BACKGROUND OF THE INVENTION
[0002] The present invention relates to therapeutic uses of bactericidal/permeability increasing (BPI) protein products for the treatment of conditions related
to gram-negative bacterial infection and the conditions not directly associated with gram-negative bacterial infection, including neutralization of the
anti-coagulant properties of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation and treatment of chronic inflammatory disease states
such as arthritis.
[0003] Heparin Binding
[0004] Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. Although
others may be present, the main sugars occurring in heparin are: (1) .alpha.-L-iduronic acid 2-sulfate, (2) 2-deoxy-2-sulfamino-.alpha.-D-glucose 6-sulfate,
(3) .beta.-D-glucuronic acid, (4) 2-acetamido-2-deoxy-.alpha.-D-glucose, and (5) .alpha.-L-iduronic acid. These sugars are present in decreasing amounts,
usually in the order (2)>(1)>(4)>(3)>(5), and are joined by glycosidic linkages, forming polymers of varying sizes. Heparin is strongly acidic because of its
content of covalently linked sulfate and carboxylic acid groups. Heparin is found within mast cell granules and is released upon degranulation. A cell
associated form of heparin is termed heparan sulfate. Heparan sulfate is a broad term used to describe a variety of sulfated proteoglycans (HSPG's) found
with a near-ubiquitous distribution on mammalian cell surface membranes and in the extracellular matrix. HSPG contains a variable percentage of pentameric
heparin-like sequences that function in a similar fashion as soluble heparin. The HSPG's serve as a repository for antithrombin III (ATIII) and for
heparin-binding growth factors such as fibroblast growth factors (FGF) 1-5, IL-8, GM-CSF and IL-3. Folkman, et al., Inflammation: Basic Principles and
Clinical Correlates, 2d Ed. Chapter 40, pp 821-839 (1992). In fact, cells made genetically deficient in HSPG's require exogenous heparin for growth.
[0005] Heparin is commonly administered in doses of up to 400 U/kg during surgical procedures such as cardiopulmonary bypass, cardiac catheterization
and hemodialysis procedures in order to prevent blood coagulation during such procedures. The anticoagulant effect of heparin in blood is a result of the
interaction of heparin with ATIII. The heparin/ATIII complex is a potent inhibitor of many of the clotting factors of the coagulation cascade. Specific
inhibition has been demonstrated for activated Factors IXa, Xa, XIa, XIIIa and thrombin. The heparin/ATIII complex has the highest affinity for Factor Xa and
thrombin which are common to both the intrinsic and extrinsic clotting pathways involved as the last two steps of the clotting cascade that results in the
conversion of fibrinogen to fibrin.
[0006] When heparin is administered for anticoagulant effects during surgery, it is an important aspect of post-surgical therapy that the effects of heparin are
promptly neutralized so that normal coagulation function can be restored. Currently protamine is used to neutralize heparin. Protamines are simple proteins of
low molecular weight which are commonly isolated from salmon sperm. They are rich in arginine amino acid residues and strongly basic. Administered alone,
protamines (usually in the form of protamine sulfate) have anti-coagulant effects. When administered in the presence of heparin, a stable complex is formed
and the anticoagulant activity of both drugs is lost. Significant hypotensive and anaphylactoid effects of protamine have limited its clinical utility.
[0007] Other reported compounds which have heparin neutralizing activity include platelet factor 4 (PF4) and major basic protein, see U.S. Pat. No.
5,086,164. Major basic protein demonstrates heparin neutralizing activity but is also highly toxic.
[0008] Angiogenesis
[0009] Angiogenesis is closely associated with endothelial cell proliferation and constitutes the development of new capillary blood vessels. As such, it is an
important process in mammalian development and growth, and in menstruation processes. The release of angiogenic growth factors, such as fibroblast growth
factors 1-5, induces proliferation of endothelial cells via a heparin-dependent receptor binding mechanism. See Yayon et al., Cell, 64:841-848 (1991). These
heparin-binding growth factors can be released due to vascular trauma (wound healing), immune stimuli (autoimmune disease), inflammatory mediators
(prostaglandins) and from tumor cells.
[0010] Angiogenesis is also associated with a number of pathological conditions in which it would be desirable to inhibit such new blood vessel development.
As one example, angiogenesis is critical to the growth, proliferation, and metastasis of various tumors. Other pathological conditions associated with
angiogenesis include diabetic retinopathy, retrolental fibroplasia, neovascular glaucoma, psoriasis, angiofibromas, immune and non-immune inflammation
including rheumatoid arthritis, capillary proliferation within atherosclerotic plaques, hemangiomas, endometriosis and Kaposi's Sarcoma.
[0011] Folkman, et al., supra, discloses that psoriatic lesions in the skin are dominated by epithelial proliferation, neovascularization, and an infiltrate of
inflammatory cells. It is unclear, however, whether angiogenesis is a step in the pathogenesis of psoriasis or a secondary phenomenon.
[0012] Several substances are known to function as angiogenesis inhibitors and have been reported to inhibit tumor angiogenesis, to prevent the onset of
arthritis and to inhibit established arthritis in collagen-induced arthritis models, Peacock et al., J. Exp. Med., 175:1135-1138 (1992). As one example,
protamine is known to inhibit tumor angiogenesis and subsequent tumor growth. According to Taylor et al., Nature, 297:307-312 (1982) protamine's
anti-angiogenic activity is attributed to its ability to bind heparin. PF4 is also known to exhibit anti-angiogenic activity. Of interest to the present application is
U.S. Pat. No. 5,112,946 which discloses modified PF4 and analogs thereof which have anti-angiogenic activity but lack the ability to bind heparin. PF4 has
been shown to have at least two functional properties. Heparin binding has been studied most extensively; however, PF4 was originally described to have
collagenase inhibitory properties. Collagenase inhibitors were the first inhibitors of angiogenesis to be discovered. See Folkman, et al., supra (1973). The
mutations in the heparin binding region of PF4 were not examined for their effect on collagenase inhibitory activity. Interestingly, thrombospondin is also an
inhibitor of angiogenesis and binds to heparin with a serine/tryptophan motif instead of a basic amino acid motif. Thus, there is no obvious single consensus
sequence heparin binding or for angiogenesis inhibition.
[0013] PCT Publication No. WO 92/01003 discloses the use of glycosaminoglycan (heparin) derivatives and their use as inhibitors of tumor invasiveness.
Heparin derivatives are disclosed which are described as being substantially devoid of anticoagulation activity and which impede the formation of tumor
metastases in a host.
[0014] Chronic Inflammation
[0015] Chronic inflammation is usually accompanied by angiogenesis. Arthritis is a chronic syndrome characterized by the inflammation of the peripheral
joints accompanied by synovial thickening and the influx of immune factors and cells such as polymorphonuclear leukocytes (PMN). In rheumatoid arthritis,
the inflammation is immune driven, while in reactive arthritis, inflammation is associated with infection of the synovial tissue with pyogenic bacteria or other
infectious agents. Folkman, et al., supra (1973) also note that many types of arthritis progress from a stage dominated by an inflammatory infiltrate in the
joint to a later stage in which a neovascular pannus invades the joint and begins to destroy cartilage. While it is unclear whether angiogenesis in arthritis is a
causative component of the disease, and not an epiphenomenon, there is evidence that angiogenesis is necessary for the maintenance of synovitis in
rheumatoid arthritis. While nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and other therapies have provided improvements in relief for
treatment of arthritis, there remains a need in the art for more effective therapies for arthritis and other inflammatory diseases.
[0016] Inflammation and angiogenesis are now understood to be separable but not mutually exclusive processes. Specific angiogenic proteins have been
discovered that stimulate angiogenesis without inflammation whereas angiostatic steroids can inhibit angiogenesis without decreasing acute inflammation. See
See Folkman, et al., supra (1973). Interestingly, endotoxin has been identified as the most potent exogenous stimulator of angiogenesis through its
stimulation of macrophage cytokines and growth factors.
[0017] Bactericidal/Permeability-Increasing Protein
[0018] Bactericidal/permeability-increasing protein (BPI) is a protein isolated from the granules of mammalian PMNs, which are blood cells essential in the
defense against invading microorganisms. Human BPI protein has been isolated from polymorphonuclear neutrophils by acid extraction combined with either
ion exchange chromatography [Elsbach, J. Biol. Chem., 254:11000 (1979)] or E. coli affinity chromatography [Weiss, et al., Blood, 69:652 (1987)], referred
to herein as natural BPI, and has potent bactericidal activity against a broad spectrum of gram-negative bacteria. The molecular weight of human BPI is
approximately 55,000 daltons (55 kD). The amino acid sequence of the entire human BPI protein, as well as the DNA encoding the protein, have been
elucidated in FIG. 1 of Gray, et al., J. Biol. Chem., 264:9505 (1989), incorporated herein by reference.
[0019] The bactericidal effect of BPI has been shown to be highly specific to sensitive gram-negative species, while non-toxic for other microorganisms and
for eukaryotic cells. The precise mechanism by which BPI kills bacteria is as yet unknown, but it is known that BPI must first attach to the surface of
susceptible gram-negative bacteria. This initial binding of BPI to the bacteria involves electrostatic interactions between the basic BPI protein and the
negatively charged sites on lipopolysaccharides (LPS). LPS has been referred to as "endotoxin" because of the potent inflammatory response that it
stimulates. LPS induces the release of mediators by host inflammatory cells which may ultimately result in irreversible endotoxic shock. BPI binds to lipid A,
the most toxic and most biologically active component of LPS.
[0020] In susceptible bacteria, BPI binding is thought to disrupt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and
peptidoglycans, altering the permeability of the cell's outer membrane, and initiating events that ultimately lead to cell death. Elsbach and Weiss, Inflammation:
Basic Principles and Clinical Correlates, eds. Gallin, et al., Chapter 30, Review Press, Ltd. (1992). BPI is thought to act in two stages. The first is a sublethal
stage that is characterized by immediate growth arrest, permeabilization of the outer membrane and selective activation of bacterial enzymes that hydrolyze
phospholipids and peptidoglycan. Bacteria at this stage can be rescued by plating on serum albumin supplemented media. The second stage, defined by
growth inhibition that cannot be reversed by serum albumin, occurs after prolonged exposure of the bacteria to BPI and is characterized by extensive
physiologic and structural changes, including penetration of the cytoplasmic membrane.
[0021] BPI is also capable of neutralizing the endotoxic properties of LPS to which it binds. Because of its gram-negative bactericidal properties and its
ability to neutralize LPS, BPI can be utilized for the treatment of mammals suffering from diseases caused by gram-negative bacteria, such as bacteremia or
sepsis.
[0022] A proteolytic fragment corresponding to the N-terminal portion of human BPI holoprotein possesses the lipid A binding and antibacterial activity of
the naturally-derived 55 kD human holoprotein. In contrast to the N-terminal portion, the C-terminal region of the isolated human BPI protein displays only
slightly detectable anti-bacterial activity. Ooi, et al., J. Exp. Med., 174:649 (1991). A BPI N-terminal fragment, comprising approximately the first 199 amino
acid residues of the human BPI holoprotein and referred to as "rBPI.sub.23", has been produced by recombinant means as a 23 kD protein.
Gazzano-Santoro, et al., Infect. Immun. 60:4754-4761 (1992).
[0023] Of interest to the present application are the disclosures in PCT International Application PCT/US91/05758 having publication No. WO 92/03535
relating to compositions comprising a BPI protein and an anionic compound which compositions are said to exhibit (1) no bactericidal activity and (2)
endotoxin neutralizing activity. Anionic compounds are preferably a protein such as serum albumin but can also be a proteoglycan such as heparin. In
addition, Weiss, et al., J. Clin. Invest., 55:3342 (1975) discloses that heparin sulfate and LPS bind to block expression of the permeability increasing activity
of BPI. Neither reference discloses neutralization of heparin by combination with BPI, however.
[0024] There continues to exist a need in the art for new products and methods for use in neutralization of heparin, inhibition of tumor and angiogenesis,
endothelial cell proliferation and treatment of chronic inflammation. |
